Skip to main content
Clinical Trials/DRKS00006061
DRKS00006061
Recruiting
未知

Cardiac Magnetic Resonance Spectroscopic Correlates of Cardiac Sympathetic Denervation in Parkinson’s disease: A Comparison with MSA-P and Healthy Controls

Abteilung für Neurobiologie, Department für Neurologie, Medizinische Universität Innsbruck0 sites60 target enrollmentMay 30, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
G20
Sponsor
Abteilung für Neurobiologie, Department für Neurologie, Medizinische Universität Innsbruck
Enrollment
60
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 30, 2014
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Abteilung für Neurobiologie, Department für Neurologie, Medizinische Universität Innsbruck

Eligibility Criteria

Inclusion Criteria

  • PD Patients:
  • Clinical diagnosis of PD according to the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria (Hughes, Ben\-Shlomo et al. 1992\)
  • Current age between 30 – 90 years
  • The subject must be able to give written informed consent (full contractual capability)
  • The subject must be willing to participate in all study related activities and visits
  • MSA Patients:
  • Clinical diagnosis of probable MSA\-P according to the revised Gilman criteria (Gilman, Wenning et al. 2008\)
  • Current age between 30 – 90 years
  • The subject must be able to give written informed consent (full contractual capability)
  • The subject must be willing to participate in all study related activities and visits

Exclusion Criteria

  • History of other major neurological or psychiatric disorders or conditions
  • History of coronary heart disease, ischemic and non\-ischemic cardiomyopathy
  • Heart failure determined by echocardiography (ejection fraction below reference range)
  • Cardiac denervation unrelated to parkinsonism (e.g. diabetic neuropathy or heart transplantation as determined by history or laboratory findings \[i.e. HbA1c])
  • Known or suspected pregnancy or breastfeeding
  • Presence of contraindication to MRI (e.g. implants)
  • Dependence on any drug that intereferes with MIBG

Outcomes

Primary Outcomes

Not specified

Similar Trials